Florida Doc Agresti Banned from Prescribing After Fraud Conviction Hits
Published Date: 7/8/2025
Notice
Summary
Dr. Mark Agresti from Florida lost his DEA registration because he was convicted of health care fraud and excluded from federal health programs. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can no longer legally prescribe controlled substances, effective immediately, impacting his medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked; Prescribing Stopped
The DEA revoked Mark Agresti, M.D.'s Certificate of Registration No. BA2032441, effective August 6, 2025. Because his registration is revoked and future Florida registration applications are denied, he can no longer legally hold or renew a registration to prescribe controlled substances in Florida or lawfully prescribe controlled substances under that DEA number.
Mandatory Exclusion from Federal Health Programs
The record shows HHS/OIG mandatorily excluded Mark Agresti, M.D. from Medicare, Medicaid, and all Federal health care programs effective January 19, 2023, for a minimum period of 47 years. This exclusion follows his 2022 conviction for one count of conspiracy to commit health care fraud and wire fraud and 11 counts of health care fraud.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-12609 — Tanya Newlove, N.P.; Decision and Order
Tanya Newlove, a nurse practitioner from Illinois, lost her DEA registration because her state licenses expired and she didn’t ask for a hearing to defend herself. This means she can no longer handle controlled substances legally, effective immediately. If you’re a healthcare provider, this reminds you to keep your licenses current or risk losing important permissions.
Next: 2025-12611 — Notice of Request To Release Airport Property; Waterloo Regional Airport (ALO), Waterloo, Iowa
The FAA wants to give up two pieces of land at Waterloo Regional Airport in Iowa and is asking the public what they think. This means the airport can use the land for other things, possibly bringing in new opportunities or money. If you care about the airport or local land use, now’s the time to speak up!